Misonix to Participate in Three Upcoming Investor Conferences
November 04 2019 - 8:30AM
Misonix, Inc. (NASDAQ: MSON) (“Misonix” or the “Company”), a
provider of minimally invasive therapeutic ultrasonic medical
devices and regenerative products that enhance clinical outcomes,
today announced that management will be participating in three
upcoming investor conferences:
- 10th Annual Craig-Hallum Alpha Select
Conference
- Date: Tuesday, November 12, 2019
- Location: Sheraton New York Times Square Hotel, New York,
N.Y.
- Canaccord Genuity Medical Technologies &
Diagnostics Forum
- Date: Thursday, November 21, 2019
- Location: Westin Grand Central Hotel, New York,
N.Y.
- Piper Jaffray 31st Annual Healthcare
Conference
- Date: Thursday, December 5, 2019
- Location: Lotte New York Palace Hotel, New York, N.Y.
Misonix President and Chief Executive Officer,
Stavros Vizirgianakis, along with Joe Dwyer, Misonix Chief
Financial Officer, will be available to meet with institutional
investors in one-on-one meetings throughout the day at each of the
events.
The Misonix investor presentation is available
in the “Investor Relations” section of the Company’s website at
www.misonix.com. If you have questions about Misonix or are
interested in conducting a conference call or meeting with
management, please contact the Company’s investor relations firm,
JCIR, at (212) 835-8500 or via email at mson@jcir.com.
About Misonix, Inc.Misonix,
Inc. (Nasdaq: MSON) designs, manufactures and markets minimally
invasive ultrasonic medical devices used for precise bone
sculpting, removal of soft and hard tumors and tissue debridement,
primarily in the areas of neurosurgery, orthopedic surgery, plastic
surgery, wound care and maxillo-facial surgery. The Company
combined its SonicOne wound debridement application with the
recently acquired TheraSkin product, a leading cellular skin
substitute indicated for all wound treatments. The Company’s sales
force operates as two divisions, Surgical (Neuro and Spine
Applications) and Wound. At Misonix, Better Matters to us. That is
why throughout the Company’s history, Misonix has maintained its
commitment to medical technology innovation and the development of
products that radically improve patient outcomes. Additional
information is available on the Company's web site at
www.misonix.com.
Contact: |
|
Joe Dwyer |
Norberto Aja, Jennifer
Neuman |
Chief Financial Officer |
JCIR |
Misonix, Inc. |
212-835-8500 or
mson@jcir.com |
631-694-9555 |
|
Misonix (NASDAQ:MSON)
Historical Stock Chart
From Mar 2024 to Apr 2024
Misonix (NASDAQ:MSON)
Historical Stock Chart
From Apr 2023 to Apr 2024